S&P 500   3,331.07 (+0.31%)
DOW   29,268.20 (+0.25%)
QQQ   224.89 (+0.72%)
AAPL   319.60 (+0.96%)
FB   222.16 (+0.33%)
MSFT   166.65 (+0.09%)
GOOGL   1,492.74 (+0.71%)
AMZN   1,896.99 (+0.26%)
CGC   24.45 (+1.24%)
NVDA   252.13 (+1.69%)
BABA   223.81 (+0.70%)
MU   59.73 (+1.29%)
GE   11.39 (-2.40%)
TSLA   586.84 (+7.24%)
AMD   51.81 (+1.49%)
T   39.06 (+1.40%)
ACB   2.05 (+1.99%)
NFLX   327.81 (-3.05%)
PRI   126.56 (+0.12%)
BAC   34.32 (+0.18%)
DIS   144.04 (+0.33%)
GILD   63.11 (+0.77%)
S&P 500   3,331.07 (+0.31%)
DOW   29,268.20 (+0.25%)
QQQ   224.89 (+0.72%)
AAPL   319.60 (+0.96%)
FB   222.16 (+0.33%)
MSFT   166.65 (+0.09%)
GOOGL   1,492.74 (+0.71%)
AMZN   1,896.99 (+0.26%)
CGC   24.45 (+1.24%)
NVDA   252.13 (+1.69%)
BABA   223.81 (+0.70%)
MU   59.73 (+1.29%)
GE   11.39 (-2.40%)
TSLA   586.84 (+7.24%)
AMD   51.81 (+1.49%)
T   39.06 (+1.40%)
ACB   2.05 (+1.99%)
NFLX   327.81 (-3.05%)
PRI   126.56 (+0.12%)
BAC   34.32 (+0.18%)
DIS   144.04 (+0.33%)
GILD   63.11 (+0.77%)
S&P 500   3,331.07 (+0.31%)
DOW   29,268.20 (+0.25%)
QQQ   224.89 (+0.72%)
AAPL   319.60 (+0.96%)
FB   222.16 (+0.33%)
MSFT   166.65 (+0.09%)
GOOGL   1,492.74 (+0.71%)
AMZN   1,896.99 (+0.26%)
CGC   24.45 (+1.24%)
NVDA   252.13 (+1.69%)
BABA   223.81 (+0.70%)
MU   59.73 (+1.29%)
GE   11.39 (-2.40%)
TSLA   586.84 (+7.24%)
AMD   51.81 (+1.49%)
T   39.06 (+1.40%)
ACB   2.05 (+1.99%)
NFLX   327.81 (-3.05%)
PRI   126.56 (+0.12%)
BAC   34.32 (+0.18%)
DIS   144.04 (+0.33%)
GILD   63.11 (+0.77%)
S&P 500   3,331.07 (+0.31%)
DOW   29,268.20 (+0.25%)
QQQ   224.89 (+0.72%)
AAPL   319.60 (+0.96%)
FB   222.16 (+0.33%)
MSFT   166.65 (+0.09%)
GOOGL   1,492.74 (+0.71%)
AMZN   1,896.99 (+0.26%)
CGC   24.45 (+1.24%)
NVDA   252.13 (+1.69%)
BABA   223.81 (+0.70%)
MU   59.73 (+1.29%)
GE   11.39 (-2.40%)
TSLA   586.84 (+7.24%)
AMD   51.81 (+1.49%)
T   39.06 (+1.40%)
ACB   2.05 (+1.99%)
NFLX   327.81 (-3.05%)
PRI   126.56 (+0.12%)
BAC   34.32 (+0.18%)
DIS   144.04 (+0.33%)
GILD   63.11 (+0.77%)
Log in
(Ad)
And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

$21.86
+0.30 (+1.39 %)
(As of 01/22/2020 01:24 PM ET)
Today's Range
$21.20
Now: $21.86
$22.08
50-Day Range
$19.45
MA: $21.32
$24.07
52-Week Range
$10.01
Now: $21.86
$24.72
Volume24,560 shs
Average Volume295,228 shs
Market Capitalization$732.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:COLL
CUSIPN/A
Phone781-713-3699

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$280.41 million
Cash Flow$2.02 per share
Book Value$2.75 per share

Profitability

Net Income$-39,130,000.00

Miscellaneous

Employees266
Market Cap$732.97 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive COLL News and Ratings via Email

Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its quarterly earnings data on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.03. The specialty pharmaceutical company earned $72.94 million during the quarter, compared to the consensus estimate of $74.32 million. Collegium Pharmaceutical had a negative return on equity of 13.14% and a negative net margin of 3.86%. The business's quarterly revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company earned ($0.50) earnings per share. View Collegium Pharmaceutical's Earnings History.

When is Collegium Pharmaceutical's next earnings date?

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Collegium Pharmaceutical.

What price target have analysts set for COLL?

6 brokerages have issued 1 year price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $29.33 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

What is the consensus analysts' recommendation for Collegium Pharmaceutical?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Has Collegium Pharmaceutical been receiving favorable news coverage?

News coverage about COLL stock has been trending negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Collegium Pharmaceutical.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,040,000 shares, an increase of 22.9% from the December 15th total of 1,660,000 shares. Based on an average daily trading volume, of 444,800 shares, the short-interest ratio is currently 4.6 days. Currently, 7.0% of the shares of the company are short sold. View Collegium Pharmaceutical's Current Options Chain.

Who are some of Collegium Pharmaceutical's key competitors?

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Celgene (CELG), Bausch Health Companies (BHC), Canopy Growth (CGC), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT) and Ocular Therapeutix (OCUL).

Who are Collegium Pharmaceutical's key executives?

Collegium Pharmaceutical's management team includes the folowing people:
  • Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)
  • Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
  • Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
  • Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
  • Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35)

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $21.85.

How big of a company is Collegium Pharmaceutical?

Collegium Pharmaceutical has a market capitalization of $732.63 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

What is Collegium Pharmaceutical's official website?

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.


MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel